NTera‑2 human testicular embryonic carcinoma cell line was stained with Mouse Anti-Human/Mouse SSEA‑4 Alexa Fluor® 647‑conjugated Monoclonal Antibody (Catalog # FAB1435R, filled histogram) or isotype control ...read more
12 months from date of receipt, 2 to 8 °C as supplied.
Supplied in a saline solution containing BSA and Sodium Azide.
Protein A or G purified from hybridoma culture supernatant
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for SSEA-4 Antibody (MC-813-70) [Alexa Fluor® 647]
SSEA-4 is expressed on the surface of human embryonal carcinoma (EC) cells (the pluripotent stem cells of teratocarcinomas), human embryonic germ cells (EG), and human embryonic stem cells (ES). Expression of SSEA-4 is down-regulated following differentiation of human EC cells. In contrast, the differentiation of murine EC and ES cells may be accompanied by an increase in SSEA-4 expression (1-4).
Shevinsky, L.H. et al. (1982) Cell 30:697.
Kannagi, R. et al. (1983) EMBO J. 2:2355.
Thomson, J.A. and J.S. Odorico (2000) Trends Biotechnol. 18:53.
Draper, J.S. et al. (2002) J. Anat. 200:249.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Publications for SSEA-4 Antibody (FAB1435R)(1)
We have publications tested in 1 confirmed species: Human.
We have publications tested in 1 application: Flow Cytometry.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our SSEA-4 Antibody (MC-813-70) [Alexa Fluor® 647] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.